Cambridge and London, UK, 18 January 2021:
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
Cambridge, United Kingdom – 14 January 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board.
Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.
Cambridge, UK, 13 January 2021: Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, was honored with a Employees’ Choice Award recognizing the Best Places to Work in 2021 by Glassdoor, the worldwide leader on insights about jobs and companies.
Cambridge animal health technology pioneer PetMedix has clinched a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.
Cambridge, UK, 12 January 2021: CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)1.
Tokyo, Japan and Cambridge, UK, 12 January 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
Cambridge, UK and New York City, USA, 12th January 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront
Wädenswil/Zurich, Switzerland and Saffron Walden, UK, 12th January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has invested in the WAVEdelta instrument from Creoptix AG. This instrument utilizes Grating-Coupled Interferometry (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner.